Jean-Baptiste Thibert: Protecting Fundamental Human Rights to Improve Patient Access and Donor Health
Jean-Baptiste Thibert, Medical and Biology Director at EFS, shared a post on LinkedIn recent article he and his colleagues co-authored, adding:
“Excited to share our latest collaborative work on protecting fundamental human rights, thereby improving both patient access to plasma-derived therapies and donor health protection.
Patient access to plasma-derived medicinal products and blood donor protection are challenges that are currently hard to meet and often presented like mutually exclusive choices.
We show how advantageous it could be to reposition the fundamental right to health protection as an input parameter for decisions on the transfusion and plasma supply chain.
Placing both patients and donors under the umbrella of fundamental human rights allows to act not as if a choice has to be made between patients and donors, but in ways that protect them both.”
Katja van den Hurk, Head of Donor Studies and Senior Epidemiologist/Principal Investigator at Sanquin, Professor of Donor Health at University of Amsterdam, shared this post on LinkedIn, adding:
“Happy to see this collaborative work published!
Our paper discusses how placing patients and donors under the same human-rights framework can help address challenges in plasma supply; supporting both access to plasma-derived medicinal products and donor health protection.”
Title: Protection of fundamental human rights by improving patient access to plasma-derived therapies and donor health protection
Authors: Jean-Baptiste Thibert, Leni von Bonsdorff, Jean-Philippe Plançon, Vincenzo de Angelis, Cynthia So-Osman, Christian Erikstrup, Pierre Tiberghien, Katja van den Hurk
Read the Full Article on Vox Sanguinis
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS